Handelsbanken Fonder AB Acquires 4,400 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Handelsbanken Fonder AB increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 16.2% during the fourth quarter, Holdings Channel reports. The fund owned 31,500 shares of the company’s stock after purchasing an additional 4,400 shares during the period. Handelsbanken Fonder AB’s holdings in Vaxcyte were worth $2,579,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of PCVX. Janus Henderson Group PLC boosted its position in Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after buying an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. boosted its position in Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after buying an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Vaxcyte by 47.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock valued at $148,075,000 after buying an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Vaxcyte in the 3rd quarter valued at $41,114,000. Finally, Franklin Resources Inc. boosted its position in Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after buying an additional 324,560 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price objective on shares of Vaxcyte in a research report on Tuesday, February 11th. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $127.71.

Insider Activity

In related news, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the sale, the chief executive officer now owns 450,301 shares of the company’s stock, valued at approximately $41,630,327.45. This trade represents a 3.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,180,820.35. The trade was a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 76,616 shares of company stock valued at $6,766,481 in the last 90 days. 3.10% of the stock is owned by company insiders.

Vaxcyte Stock Up 2.4 %

PCVX stock opened at $81.68 on Tuesday. The business’s fifty day moving average is $85.46 and its 200-day moving average is $94.99. The company has a market cap of $10.18 billion, a P/E ratio of -17.76 and a beta of 0.98. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.